DCVC Opportunity Fund II GP, LLC
CIK
1668343
Location
PALO ALTO, CA
Portfolio Value
Micro
$13,866,317
Diversification
Highly concentrated
Filing Date
Global Rank
#7,593
/ 8,232
▲ 117
Top Industry
Biotechnology
87.5%
3Y Alpha vs SPY
-39.0%
Period ended 2 months ago
Filed May 15, 2026 · 29d
14 quarters · since Dec 2021
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
-45.2%
SPY
+76.5%
Annualised alpha
-39.0%
Max drawdown
−69.8%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
2 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
87.5%
−9.9 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
7,809
Highly concentrated−1,689
Portfolio Trend
14 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 87.5% | $12,130,002 |
| Technology | 12.5% | $1,736,315 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IONQ | IonQ, Inc. | +50,705 | 60,226 | $1,736,315 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reducedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
2 positions ·
$13,866,317 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RXRX |
Recursion Pharmaceuticals, Inc.
Healthcare
|
Held | 3,951,141 | $12,130,002 | 87.48% | |
| IONQ |
IonQ, Inc.
Technology
|
Added | 60,226 | $1,736,315 | 12.52% |